title: Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma.
abstract: OBJECTIVE
  To evaluate the impact of standardized staging, surgery and adjuvant chemotherapy on survival of patients with completely resected early ovarian carcinoma.
  
  
  METHODS
  We performed a multicentric retrospective analysis of 283 patients with early stage ovarian carcinoma consecutively treated between 1977 and 1993. Borderline tumours were excluded. A comprehensive staging was performed during initial laparotomy. Patients were treated by standardized surgical resection and all excepted stage IA received a 6-course adjuvant chemotherapy.
  
  
  RESULTS
  Eighty patients were excluded because of incorrect substaging, inadequate surgery and adjuvant therapy. The analysis was performed on 203 patients with completely resected early stage ovarian cancer (139, stage I; 64, stage II). Relapse-free survival and overall survival rates for stage I were 66 and 69%, respectively. Relapse-free survival and overall survival rates for stage II were 57 and 61% respectively. Median time of relapse was 18 months (range, 1-107 months). Sites of relapse were peritoneum (45%), retroperitoneal lymph nodes (37%) and distant metastases (18%). Relapses occurring within 18 months had a median survival after relapse of 9 months while later relapses had a median survival of 22 months (P = 0.005). There was no significant difference in relapse-free and overall survival according to the age, performance status and pathology. Cisplatin-based chemotherapy improved the 10-year overall survival of patients with stage IIB and IIC as compared to chemotherapy without cisplatin (oral melphalan. CMF regimen); 91 vs. 33% (P = 0.012) and 75 vs. 42% (P = 0.05), respectively. Cisplatin-based regimens did not improve survival in stage IA, IB and IIA.
  
  
  CONCLUSIONS
  Early ovarian cancers have a good prognosis after comprehensive staging, complete surgery and adjuvant chemotherapy. Cisplatin-based regimens compared to melphalan and CMF showed a significant increase of survival in stage IIB and IIC. Prognosis of relapse depends on the relapse-free interval duration.
authors.affiliation: Hôpital Saint-Antoine, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Raymond
authors.forename: Y
authors.initials: Y
authors.lastname: Drolet
authors.forename: L
authors.initials: L
authors.lastname: Marpeau
authors.forename: C
authors.initials: C
authors.lastname: Louvet
authors.forename: J
authors.initials: J
authors.lastname: Cady
authors.forename: C
authors.initials: C
authors.lastname: Tessier
authors.forename: S
authors.initials: S
authors.lastname: Faivre
authors.forename: P
authors.initials: P
authors.lastname: Ouellet
authors.forename: A
authors.initials: A
authors.lastname: Lavoie
authors.forename: E
authors.initials: E
authors.lastname: Rioux
authors.forename: A
authors.initials: A
authors.lastname: de Gramont
authors.forename: M
authors.initials: M
authors.lastname: Krulik
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000097:blood; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D018394:CA-125 Antigen; D002945:Cisplatin